文献速递造血干细胞移植与细胞治疗

靶向白消安为基础减低强度预处理联合HLA相合造血干细胞移植治愈噬血细胞性淋巴组织细胞增多症

Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.
PubMed 文献 · Blood Adv · 2020-01-01

该研究评估以靶向白消安为基础的减低强度预处理方案在噬血细胞性淋巴组织细胞增多症(HLH)患者中的疗效。25例来自7个中心的中位年龄0.68岁患者接受HLA相合相关(n=7)或无关(n=18)供者移植,所有患者均植入成功,3年总生存率和无事件生存率均为100%,无III-IV级急性移植物抗宿主病,8例(32%)发生肝窦阻塞综合征经去纤苷治疗后缓解。

要点

  • 25例HLH患者接受靶向白消安为基础减低强度预处理联合HLA相合移植,中位年龄0.68岁。
  • 所有患者植入成功,中位随访36个月时CD15+中性粒细胞、CD3+T细胞、CD16+56+NK细胞供者嵌合率中位分别为99.5%、97%、97.5%。
  • 3年总生存率和无事件生存率均为100%,无III-IV级急性GVHD,8例(32%)发生肝窦阻塞综合征经去纤苷治疗后缓解。

核心结论

  • 该以靶向白消安为基础的减低强度预处理方案在HLH患者中取得优异结果,供者嵌合稳定。

研究设计与样本

  • 研究纳入来自7个中心的25例HLH患者,中位年龄0.68岁,接受欧洲骨髓与移植学会批准的减低强度预处理方案。
  • 预处理包括靶向亚清髓性静脉白消安、静脉氟达拉滨和血清治疗:无关供者用静脉阿仑单抗(0.5-0.8 mg/kg),相关供者用静脉兔抗T细胞球蛋白。
  • 移植物来源为骨髓、外周血干细胞或脐带血,来自HLA相合相关供者(n=7)或无关供者(n=18)。
  • 评估指标包括毒性、植入、移植物抗宿主病(GVHD)、血细胞亚型供者嵌合率及总生存/无事件生存。

主要发现

  • 白消安中位总剂量为13.1 mg/kg(范围6.4-26.4),累积曲线下面积中位为63.1 mg/L×h(范围48-77)。
  • 所有患者供者细胞均植入,中性粒细胞中位植入时间为d+20,血小板中位植入时间为d+28。
  • 末次随访(中位36个月,范围8-111个月)时,CD15+中性粒细胞、CD3+T细胞、CD16+56+自然杀伤细胞的供者嵌合率中位分别为99.5%(范围10-100)、97%(范围30-100)、97.5%(范围30-100)。
  • 8例(32%)发生肝窦阻塞综合征,经去纤苷治疗后缓解。
  • 3年总生存率和无事件生存率均为100%;无患者发生III-IV级急性GVHD,4%发生局限性慢性GVHD。

临床怎么用

  • 原文结论认为该方案在HLH患者中取得优异结果并实现稳定供者嵌合,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reduced-intensity/reduced-toxicity conditioning and allogeneic T-cell replete hematopoietic stem cell transplantation are curative in patients with hemophagocytic lymphohistiocytosis (HLH). Unstable donor chimerism (DC) and relapses are clinical challenges . We examined the effect of a reduced-intensity conditioning regimen based on targeted busulfan to enhance myeloid DC in HLH. The European Society for Bone and Marrow Transplantation-approved reduced-intensity conditioning protocol comprised targeted submyeloablative IV busulfan, IV fludarabine, and serotherapy comprising IV alemtuzumab (0.5-0.8 mg/kg) for unrelated-donor and IV rabbit anti-T-cell globulin for related-donor transplants. We assessed toxicity, engraftment, graft-versus-host disease (GHVD), DC in blood cell subtypes, and overall survival/event-free survival. Twenty-five patients from 7 centers were treated (median age, 0.68 year). The median total dose and cumulative area under the curve of busulfan was 13.1 mg/kg (6.4-26.4) and 63.1 mg/L × h (48-77), respectively. Bone marrow, peripheral blood stem cell, or cord blood transplants from HLA-matched related (n = 7) or unrelated (n = 18) donors were administered. Donor cells engrafted in all patients (median: neutrophils d+20/platelets d+28). At last follow-up (median, 36 months; range, 8-111 months), the median DC of CD15+ neutrophils, CD3+ T cells, and CD16+56+ natural killer cells was 99.5% (10-100), 97% (30-100), and 97.5% (30-100), respectively. Eight patients (32%) developed sinusoidal obstruction syndrome, resolving after defibrotide treatment. The 3-year overall survival and event-free survival rates were both 100%. None of the patients developed acute grade III to IV GHVD. Limited chronic GVHD was encountered in 4%. This regimen achieves excellent results with stable DC in patients with HLH.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 2020. PMID: 32384542. doi:10.1182/bloodadvances.2020001748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。